What sector is IMRX in?

Immuneering Corporation Class A Common Stock (IMRX) operates in the Healthcare sector, specifically in the PHARMACEUTICAL PREPARATIONS industry.

What is IMRX's market cap?

Immuneering Corporation Class A Common Stock (IMRX) has a market capitalization of $338M.

How can I analyze IMRX stock?

Valhalla provides comprehensive analysis for IMRX including institutional trade flow, dark pool activity, options data, technical indicators, and proprietary scoring. Visit valhalla-labs.io/stocks/IMRX for a full breakdown.

Where can I find institutional trades for IMRX?

Valhalla tracks real-time institutional trade flow for IMRX, including dark pool blocks, lit block trades, and sweep orders. These insights help identify where smart money is positioned.

IMRX

Q: What is IMRX (Immuneering Corporation Class A Common Stock)?

Immuneering Corporation Class A Common Stock (IMRX) is a healthcare company in the pharmaceutical preparations industry. Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients

Immuneering Corporation Class A Common Stock

Healthcare — PHARMACEUTICAL PREPARATIONS

Valhalla Score 64

$5.38

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Latest News

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -...globenewswire.com — Apr 21, 2026

IMRX Data Insights

Dark pool activity detected in the last 5 trading days

Subscribe for full dark pool analysis, institutional flow, and real-time alerts.

📊 Key Statistics

Market Cap$338M

P/E Ratio—

EPS (TTM)—

EPS YoY—

Revenue YoY—

Float—

Short Float %—

Inst. Ownership—

Sector RS—

📈 Fundamentals

ROE—

ROIC—

ROA—

Current Ratio—

Debt/Equity—

Gross Margin—

Net Margin—

Dividend Yield—

Next Earnings—

⚡ Options Summary

Call OI—

Put OI—

P/C Ratio (OI)—

Gamma Environment—

Max Pain—

Call Wall—

Put Wall—

🎯 Analyst Estimates

Consensus Target—

High Target—

Low Target—

Analysts—

Upside/Downside—

📋 Quarterly Financials

Period	Revenue	Rev YoY	EPS	EPS YoY	Gross Margin

Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

Type	Strike	Exp	Size	Premium	Time

Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

Type	Price	Size	Value	Venue	Time

Start Free Trial Full insider & congressional trade history

👤 Insider Trades

Name	Type	Shares	Price	Date

Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

Institution	Shares	Value	% of Class